MP2-03 PROGNOSTIC AND PREDICTIVE VALUE OF EPIGENETIC BIOMARKERS IN UPPER TRACT UROTHELIAL CARCINOMA
Gengyan Xiong,Jin Liu,Dong Fang,Xuesong Li,Liqun Zhou
DOI: https://doi.org/10.1016/j.juro.2015.02.126
2015-01-01
Abstract:You have accessJournal of UrologyBladder Cancer: Upper Tract TCC I1 Apr 2015MP2-03 PROGNOSTIC AND PREDICTIVE VALUE OF EPIGENETIC BIOMARKERS IN UPPER TRACT UROTHELIAL CARCINOMA Gengyan Xiong, Jin Liu, Dong Fang, Xuesong Li, and Liqun Zhou Gengyan XiongGengyan Xiong More articles by this author , Jin LiuJin Liu More articles by this author , Dong FangDong Fang More articles by this author , Xuesong LiXuesong Li More articles by this author , and Liqun ZhouLiqun Zhou More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.126AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Epigenetic biomarkers and prognostic clinical factors in upper tract urothelial carcinoma (UTUC) are inconclusive. We conducted this study to identify gene promoter (ABCC6, BRCA1, CDH1, GDF15, HSPA2, RASSF1A, SALL3, THBS1, TMEFF2 and VIM) methylation status and predictors for UTUC patients. METHODS We prospectively collected data for pathologically diagnosed UTUC patients who were treated with surgery in Peking University First Hospital (Beijing, China) from Aug 1, 1999 to Dec 31, 2011. Analysis for hypermethylation at ten CpG islands, was performed for each DNA sample using bisulfite transformation and methylation-sensitive polymerase chain reaction (MSP). The log-rank test and Cox regression were applied to identify prognostic factors, and two nomograms were utilized to construct the prognostic model for cancer specific survival (CSS) and bladder recurrence free survival (BRFS), respectively. RESULTS Methylation in tumor tissue was detected in 14.3% for ABCC6, 17.3% for BRCA1, 14.3% for CDH1, 49.9% for GDF15, 41.2% for HSPA2, 26.6% for RASSF1A, 34.4% for SALL3, 25.2% for THBS1, 43.2% for TMEFF2 and 63.2% for VIM. Among the 687 patients analyzed, the median follow-up were 65 months (range: 3–144) for CSS and 49 months (range: 2–144) for BRFS. 225(32.8%) patients died as a consequence of UTUC and 228(33.2%) patients developed bladder recurrence (BR) during the follow-up period. Older age (p<0.001), male sex (p=0.033), tumor multifocality (p=0.008), ipsilateral hydronephrosis (p<0.001), larger main tumor diameter (>5cm, p<0.001), higher tumor stage (p<0.001), positive N status (p=0.018), methylated TMEFF2 promoter (p=0.002) and unmethylated BRCA1 promoter (p=0.004) were significantly associated with poor CSS. Tumor multifocality (p=0.002), ureteroscopy history (p=0.001), lower tumor grade (p=0.046), unmethylated promoter of GDF15 (p=0.030) and RASSF1A (p=0.001) were considered as predictors to develop BR after surgery. CONCLUSIONS In conclusion, our results suggest that different classes and degrees of gene methylation could regulate tumor malignancy and progression. Methylation occurs commonly in UTUCs, may affect carcinogenic mechanisms, and is a well predictive factor for CSS and BRFS in UTUCs. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e11 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Gengyan Xiong More articles by this author Jin Liu More articles by this author Dong Fang More articles by this author Xuesong Li More articles by this author Liqun Zhou More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...